Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

NCT01099722 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

261

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Flutiform
DRUG: Symbicort Turbohaler

Sponsor

Mundipharma Research Limited